A medication first designed to address a uncommon illness might help prolong the lives of individuals facing a severe type of ovarian cancer, as indicated by a recent clinical study. This resistant form of ovarian cancer develops when the illness advances within six months following the start of platinum-containing chemotherapy. Such therapy employs platinum-based substances to eliminate cancer cells by halting their replication. Typically, those diagnosed with this resistant ovarian cancer have a life expectancy of around one year, with few therapeutic choices available. Research featured in the Lancet examined information from 381 participants with this condition. They were given either standard therapy or relacorilant, an oral drug for managing Cushing’s syndrome, which stems from high cortisol hormone levels. Following an average monitoring period of two years, the outcomes revealed a 35% decrease in mortality risk for those on relacorilant versus standard care. On average, the relacorilant recipients survived four months longer than the comparison group. The investigators determined that these results position relacorilant as a possible new benchmark for treating this resistant ovarian cancer. In a different trial with 643 patients having the same diagnosis, those receiving pembrolizumab combined with routine care survived an average of 17.7 months, compared to 14 months for those on routine care only. Pembrolizumab functions as an immunotherapy agent that boosts the body’s defenses to target cancerous cells. In the UK, ovarian cancer ranks as the sixth most frequent cancer in females, with approximately 7,600 new diagnoses annually. It represents about 4% of female cancer incidences, leading to roughly 3,900 fatalities each year. These studies are in phase 3 and need additional assessments prior to UK approval. Nonetheless, both relacorilant and pembrolizumab have received US Food and Drug Administration approval for managing platinum-resistant ovarian cancer.
